-
Non Regulatory January 24, 2022Oasmia announces progress on the development of its next generation XR-18 drug delivery technology
-
Regulatory January 19, 2022Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB
-
Non Regulatory January 19, 2022Oasmia announces intention to change its name to Vivesto
Oasmia Pharmaceutical published its Q3 2021 report on November 18, 2021, at 08.00 am CET.
The company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by CEO Francois Martelet and CFO Fredrik Järrsten. The presentation will be in English.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program
;
In this interview with Edison, our CEO, Francois Martelet, provides an overview of the business today, the transformation over the last year and exciting plans for the year ahead.
You can view the full interview here:
#oncology
Oasmia Pharmaceutical: Edison Open House Healthcare 2022
Oasmia Pharmaceutical is a Swedish speciality pharma company focusing on its proprietary XR-17 technology platform to ...
bit.ly
Today we provided an update on the development of our next generation drug delivery technology, XR-18.
Read the full announcement here:
#biotech #oncology
Oasmia announces progress on the development of its next generation XR-18 drug delivery technology - Oasmia
Solna, Sweden 24 January 2022 – Oasmia Pharmaceutical AB (Oasmia), an oncology-focused specialty pharmaceutical company,...
bit.ly
